Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News: Intellect Neurosciences Files Orphan Drug Application in the United States for Its Clinical Candidate OX1 for the Treatment of Friedreich's Ataxia
Friedreich's Ataxia Research Alliance ("FARA") Will Partner With the Company to Facilitate Clinical Trials
http://finance.yahoo.com/news/Intellect-Neurosciences-Files-pz-3387944600.html?x=0&.v=2
NEW YORK, April 12, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS - News), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for Alzheimer's disease and other serious neurodegenerative conditions, with an internal diversified pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that it has filed an orphan drug application with the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) to have Orphan Drug Designation granted to its clinical stage drug candidate, OX1 (OXIGON(TM)) for the treatment of Friedreich's Ataxia ("FA"). The United States Orphan Drug Act of 1983 is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders.
FA is a rare, hereditary, progressive, neurodegenerative disease caused by a defective gene affecting energy production. About six thousand people in the United States are estimated to suffer from the disease. Orphan Drug designation would provide a seven-year term of market exclusivity for OX1 if ultimately approved by the FDA pending successful outcome of planned clinical trials and would enable the Company to take advantage of various financial and regulatory benefits, including government grants for conducting clinical trials, waiver of FDA user fees and certain tax credits. The Company anticipates filing for Orphan Drug designation in Europe as well. The Company recently reported obtaining a positive clinical data report from human Phase 1 trials indicating that OX1 appears to be safe and well tolerated.
Dr. Daniel Chain, Chairman & CEO of Intellect commented: "The filing of an orphan drug application is an important step in our drug development strategy. Our decision pending grant of an Orphan Drug Designation, to develop OX1 as a potential ground-breaking treatment for FA, results from the convergence of two independent lines of inquiry over several years: one relates to the general properties and mechanisms of action of the drug and the other relates to a greater understanding of the pathogenic mechanisms underlying FA, especially the important role of oxidative stress. These parallel developments spanning more than a decade of research by numerous investigators, helped bring to light the strong potential of OX1 as a disease-modifying treatment for FA based on its unique multimodal antioxidant properties preventing damage to cell membranes as well as the oxidation of proteins and DNA. We believe that OX1 will ultimately prove disease modifying for FA and other neurodegenerative diseases. We are pleased by the interest shown in the program from numerous experts in FA research and grateful for the amount of assistance we received from FARA bringing us up to date on developments and clinical trial experience in this important field of biomedical research."
Jennifer Farmer, MS, CGC, Executive Director, FARA (www.curefa.org) commented: "FARA is excited that Intellect Neurosciences has decided to advance clinical research of OX1 in Friedreich's Ataxia. There is no treatment for this devastating disease. Research into the underlying mechanism of FA and damage that occurs in the cells strongly supports such a therapeutic candidate. FARA has supported the necessary clinical research infrastructure, such as a worldwide patient registry and clinical research network, to expedite planning and execution of clinical trials. We look forward to partnering with Intellect Neurosciences as their research efforts move forward."
About Friedreich's Ataxia
Friedreich's Ataxia is rare hereditary disease caused by a mutation in a gene which encodes frataxin, a protein essential for proper functioning of mitochondria, the energy pumps of the cell. In the absence of frataxin, iron in the cytoplasm builds up and causes free radical damage. The disease causes progressive damage to the nervous system, resulting in symptoms ranging from gait disturbance to speech problems; it can also lead to heart disease and diabetes. The ataxia of Friedreich's ataxia results from the degeneration of nerve tissue in the spinal cord, in particular sensory neurons essential for directing muscle movement of the arms and legs. The spinal cord becomes thinner and nerve cells lose some of their myelin sheath. The primary site of pathology is spinal cord and peripheral nerves. Symptoms typically begin sometime between the ages of 5 and 15 years, but may occur in the 20s or 30s. The disease usually presents with progressive staggering or stumbling and frequent falling. The symptoms are slow and progressive. The median age of death is 35 years. Currently there are no FDA approved drugs for FA.
About Intellect Neurosciences, Inc.
Intellect Neurosciences, Inc. is a Manhattan-based biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other serious neurodegenerative disorders. The Company's most advanced internally developed product is OX1, which has been tested in Phase 1 clinical trials and has broad potential to treat diseases in which tissues especially nervous tissue, is damaged by oxidative stress. The Company plans to conduct clinical proof of concept patient trials for OX1 in Friedreich's Ataxia, a rare inherited disease that brings about free-radical mediated progressive damage to the nervous system.
The Company's ANTISENILIN(R) monoclonal antibody technology platform for treatment of Alzheimer's disease, invented fourteen years ago by Dr. Chain, was the first to specifically target the soluble "floating" beta amyloid that is now generally believed to be responsible for most of the damage in the brain of Alzheimer's patients. Importantly, ANTISENILIN(R) antibodies bind the major classes of beta amyloid including soluble and plaque-bound forms, but avoid binding to the amyloid precursor protein from which beta amyloid is produced in the body. This high degree of specificity is an important safety feature, significantly reducing the potential for adverse affects for Alzheimer's immunotherapy. Patents have been granted in Europe, Japan and several other countries with corresponding patent applications pending in the United States. The Company is developing IN-N01, a next generation humanized monoclonal, and Recall-Vax, a vaccine technology, which has the potential to delay or prevent Alzheimer's disease in people who are at risk.
Sharebuilder Free $50 promo code: 50ws10
and link: http://content.sharebuilder.com/MgdCon/Jump/Web/welcome/allWT/?pc=50ws10
It says that it takes 4-6 weeks to show up in your account, but it's actually 3-5days after you deposit $50 or more.
No minimum account balance or maintenance fees
The same day transfer is $6.95 per trade. And a regular transfer (next day) is free. You should really look into it. There are no maintenance fees or minimum account balance. And I can give you a promo code to get you a free $50 if you open a new account and deposit more than $50. Just go on their website and look around a bit. I'm going to look at Ameritrade as well and do a comparison. I don't see how anyone could deal with that long of a transfer. A lot can happen in 3 days. Look at PSPW.
GO PSPW!!!!!!!!!!
A 3-day clear on electronic transfers? Wow! I can imagine how annoying that is when pps is constantly changing. Sharebuilder does next day transfers. Or you can do a same day transfer for a small fee. I'm like you though, when PSPW has so much potential, who cares what the pps is. PSPW is just getting started.
Go PSPW!
April 2, 2011 PSPW Released Financial Statement
http://finance.yahoo.com/q/is?s=pspw.ob
Sharebuilder as well. Buy or sell pspw.
Thanks for the observation. Great!!!
I hope not.
I have a question? What exactly is this article saying?
New news:
http://ih.advfn.com/p.php?pid=nmona&article=47110752
Sounds accurate enough to me. The PR stated "CannaBANK anticipates this landmark facility to generate in excess of $40 million in revenue annually. MJNA Management stated that the transfer will be immediately accretive to earnings."
We should see immediate increase from these assets, but exactly how many assets are they transferring? First asset will generate $40mil and second asset will generate $4mil.
You're going to make me buy more shares. Do you really think so?
GO MJNA!!!
That news is from New Zealand. MNJA is amazing. I'm looking forward to new highs.
Medical Marijuana INC Benefits From the Merger
http://topnews.net.nz/content/213310-medical-marijuana-inc-benefits-merger
Submitted by Pallavi Sharma on Thu, 03/31/2011 - 09:24
Medical Marijuana INC Benefits From the MergerThe confirmation of the merger between MEDICAL MARIJUANA INC (PINK: MJNA) and Hemp Deposit Distribution Corp., a Delaware based Co., d/b/a CannaBANK has definitely left a positive impact on the market. The stocks have increased by 400% in the past five days for the MEDICAL MARIJUANA INC (PINK: MJNA).
The Medical Marijuana industry has agreed to issue their shares to Hemp Deposit. In return, the Hemp Deposit Distribution Corp will give them their real estate, Intellectual Properties, patents and future acquisitions. They will be the major stockholders in MEDICAL MARIJUANA INC (PINK: MJNA). They will also replace the current officers and directors. They are extremely happy about the increment in the share value. The firm expects to generate more than 40 million every year from the debt-free income producing property from HDDC.
Sharebuilder is allowing buy and sell. They've already changed everything over as it appears in my account.
READ THIS: Article released today
MJNA is Top News in New Zealand
http://topnews.net.nz/content/213310-medical-marijuana-inc-benefits-merger
Medical Marijuana INC Benefits From the Merger
Submitted by Pallavi Sharma on Thu, 03/31/2011 - 09:24
Medical Marijuana INC Benefits From the MergerThe confirmation of the merger between MEDICAL MARIJUANA INC (PINK: MJNA) and Hemp Deposit Distribution Corp., a Delaware based Co., d/b/a CannaBANK has definitely left a positive impact on the market. The stocks have increased by 400% in the past five days for the MEDICAL MARIJUANA INC (PINK: MJNA).
The Medical Marijuana industry has agreed to issue their shares to Hemp Deposit. In return, the Hemp Deposit Distribution Corp will give them their real estate, Intellectual Properties, patents and future acquisitions. They will be the major stockholders in MEDICAL MARIJUANA INC (PINK: MJNA). They will also replace the current officers and directors. They are extremely happy about the increment in the share value. The firm expects to generate more than 40 million every year from the debt-free income producing property from HDDC.
That's what I meant. I'm comfortable with referring to it as 3POW. I believe the symbol should remain the same. PSPW. I want to remember where it came from and people that jump on board later will want to know why PSPW for 3Power Energy. A lot of companies change their name and keep the symbol for that purpose. It's what shareholders are familiar with.
I like 3POW for short as well.
mrvanvleet, No I've only been watching savw for a few months. When I started doing my DD, it was at .01 and I got shares at that price hoping to hold for higher numbers. Well since it has dropped, I've been picking up more shares on the way back up. This is actually something I could hold on to for a while with no worries. I'm a long. I do agree that we need more support before news so that it doesn't go downhill after news.
I know but they still have to release an actual 10k soon. Maybe on April 4 when Brendan Magone gets back. Not sure. I still believe there is good news to come.
NEW NEWS Read THIS
http://ih.advfn.com/p.php?pid=nmona&article=47091491
jaws123, no problem. I would love to see this go to new highs. If you're able to contact someone and obtain information, please inform your fellow investors. I really believe we all should send emails or contact them in some way.
I will.
I want to see PRs released consistently with GOOD NEWS.
Email: Info@SunriseConsultingGroup.net
Website: http://www.sunriseconsultinggroup.net/scg/
1280 Bison Ave., Suite B9-619
Newport Beach, CA 92660
Tel: 1 (888) 878-0179
Fax: 1 (949) 281-5441
Mine said the high was .03
It had to be a mistake, but that would've been heaven. I hate when that happens. Ihub had it as the high for a few minutes, then i refreshed. Hotstocked.com still has it as the high on their chart.
I wouldn't know how to act if it reached .03
That would be great. I'm buying more. I haven't seen the Buy Alert on this, but something is up. This company has entirely more potential than its current trading PPS. I'm holding and adding more shares. I want to see this well over .10 That would be Heaven.
They should sign contracts back to back. Walmart and McDonalds would be HUGE streams of revenue.
I really wish they would go through with the McDonalds deal. I'm in the process of writing a letter to the COO and President of McDonalds (Don Thompson) to convince him to remodel the McDonalds with SavWatts LED lighting. I wish I could get more people to do the same. He recently did an interview saying that he is remodeling McDonalds because he's gives the say so to do so. He stated that he would spend $2.4 billion to build new restaurants and remodel current ones. This was in the Black Enterprise Jan 2011 issue. I already have his fax and address. I just wish someone was with me on the convincing. Imagine how much he could save on energy costs. He's over 32,000 McDonalds in 117 Countries.
See for yourself: http://www.onlinedigitalpubs.com/publication/?i=55095&p=35
Look on page 58-60
"On March 30-31st, SavWatt and Electrical Contracting Solutions Corp. (ECS) of New York will participate together at the Green Building NY Expo (www.buildingsny.com) to be held at the Javits Center, Booth 637. Lee Rubenstein, Principal at ECS, stated, "As an Energy Solution provider, ECS is anticipating a long a bright future working with SavWatt. We are currently working in several projects ranging from partial retro fits to complete renovations which will use SavWatt LED products. We are excited to display SavWatt's Eco-Pole at this upcoming show."
-From the March 7 PR
There is news. Press Release stated:
http://finance.yahoo.com/news/SavWatt-Updates-Shareholders-iw-2821398400.html?x=0&.v=1
"On March 30-31st, SavWatt and Electrical Contracting Solutions Corp. (ECS) of New York will participate together at the Green Building NY Expo (www.buildingsny.com) to be held at the Javits Center, Booth 637. Lee Rubenstein, Principal at ECS, stated, "As an Energy Solution provider, ECS is anticipating a long a bright future working with SavWatt. We are currently working in several projects ranging from partial retro fits to complete renovations which will use SavWatt LED products. We are excited to display SavWatt's Eco-Pole at this upcoming show."
They will easily get exposure at this expo and people attending it are probably currently doing their DD on the company, which is why the PPS is going up.
New 8-k came out with the news as well.
biz.yahoo.com/e/110328/cxlt.ob8-k.html
I emailed CXLT (Net savings link) and asked if there would be any PRs anytime soon because I was concerned about the pps and believe that it has a lot more potential than its current trading value.
They responded very promptly in which I appreciate. It didn't even take 30 minutes.
CXLT Email response: (copied & pasted as is other than my contact info)
RE: Other
Monday, March 21, 2011 10:32 AM
From: "support@netsavingslink.com" <support@netsavingslink.com>
To: *****************(Me)
Thank you for emailing us. Press releases will come about in normal fashion as news is relevant. We have been working on adding vendors, acquiring members, and installing more user friendly software.
I wish I could be more specific, but we cannot comment on the stock.
We do believe that you are correct about the potential... Thank you again.
<p>
Reply to:<br />
Thank You.
</p>
A lot of stocks are declining due to the Japan incident and the Nuclear Power Plants that have exploded there. They've shut down 4 power plants and may be shutting down more. I'm glad PSPW is renewable energy and not nuclear. Any stock that is connected with nuclear energy and Japan will be on the decline for a while. Exchanges that have these stocks uplisted are seeing red overall as well.
PSPW can't be touched!!! GO PSPW!!!
Thanks. You've shed some light.
The PRs have been consistent and steady for the pass few weeks. I say this week as well. Look at the dates of the past PRs. They were only released on Mondays and Fridays pre-market. There was one released on a Thursday (March 3) that was after market, but followed by a pre-market PR that Friday. It seems that they don't do PRs midweek. Well, they haven't in a while. I'm hoping for a PR by the end of this week. That would be nice and I believe PSPW is going to make it happen. They are probably working on something as we speak.
Go PSPW!!!
So do you believe that the loan could be paid off in less than 10 years going by what PSPW has in store?
I see. Thanks for explaining that.
The loan has strict terms, don't you think.
"...fixed rate of 5% per annum for a period of 10 years."
"...the lender will also receive 20% of the annual net profits derived from each project for the duration of the loan."
"Each draw of the loan amount by the Company will be subject to customary due diligence by the lender."
3Power Energy has to pay 5% annum for 10 years AND CR&P Holding will receive 20% of the yearly profits from each project for those 10 years. 3Power is going to really come out of some cash trying to repay this loan. I'm glad you posted this because it made me read it more thoroughly. Plus CR&P Holding has to do DD on each draw of the loan amount so basically everything that 3Power says they're doing with the money has to be looked into by this lender.
Does anyone know why they would choose such a loan with strict terms as these??? 20% of yearly profits from each project could really add up over 10 years.
I knew what you meant. Was just joking with you.
GO PSPW!!!
I would say so. CXLT is far from done. IMO it's just getting started. I bought at .41 and the potential is $4.70 according to recent analyst. I will be picking up more shares before it gets too high. This is a winner!!! Look at the charts and percentage over the past 2 weeks (nothing but INCREASE).
Read: investorshub.advfn.com/boards/read_msg.aspx?message_id=60934046
NEW ARTICLE: CXLT $4.70 Potential www.businesswire.com/news/home/20110311005981/en/2nd-Opinion-Research-Issues-Report-Net-Savings
March 11, 2011 04:33 PM Eastern Daylight Time
2nd Opinion Research Issues Report on Net Savings Link, Inc. (OTCBB: CXLT) with $4.70 Potential
NEW ORLEANS--(BUSINESS WIRE)--2nd Opinion issued an informational review of Net Savings Link, Inc., an emerging online aggregator of services and coupons. The report discusses the industry and business model employed by Net Savings Link which is believed to be very attractive. According to the review, the business model is similar but different than that followed by Groupon who has pioneered this space. The analyst (Clay Mahaffey) says: “CXLT is following a much lower cost business model that is targeting large groups of members such as large organizations, labor unions, etc. to bring their membership to the Company web site. On the web site they will be able to select from thousands of deals from hundreds of vendors. It is not a ‘deal of the day’ model as followed by Groupon and so avoids the negative consequence of that model which includes low margins for vendors.” To receive a complimentary copy of the report, please visit http://2ndopinionstockresearch.com/. Disclosure: This is not a recommendation to buy or sell any security, nor a recommendation that any security is suitable for any investor. An investor should conduct their own due diligence before making any decision to buy a security. This is not an independent research report since the author received funds of twenty five thousand dollars from a third party for preparation and distribution of the material therefore has a conflict of interest. Contacts 2nd Opinion Research LLC Clay Mahaffey, 504-525-2161 Permalink: http://www.businesswire.com/news/home/20110311005981/en/2nd-Opinion-Research-Issues-Report-Net-Savings
NEW ARTICLE: CXLT $4.70 Potential
www.businesswire.com/news/home/20110311005981/en/2nd-Opinion-Research-Issues-Report-Net-Savings
March 11, 2011 04:33 PM Eastern Daylight Time
2nd Opinion Research Issues Report on Net Savings Link, Inc. (OTCBB: CXLT) with $4.70 Potential
NEW ORLEANS--(BUSINESS WIRE)--2nd Opinion issued an informational review of Net Savings Link, Inc., an emerging online aggregator of services and coupons. The report discusses the industry and business model employed by Net Savings Link which is believed to be very attractive. According to the review, the business model is similar but different than that followed by Groupon who has pioneered this space. The analyst (Clay Mahaffey) says: “CXLT is following a much lower cost business model that is targeting large groups of members such as large organizations, labor unions, etc. to bring their membership to the Company web site. On the web site they will be able to select from thousands of deals from hundreds of vendors. It is not a ‘deal of the day’ model as followed by Groupon and so avoids the negative consequence of that model which includes low margins for vendors.”
To receive a complimentary copy of the report, please visit http://2ndopinionstockresearch.com/.
Disclosure: This is not a recommendation to buy or sell any security, nor a recommendation that any security is suitable for any investor. An investor should conduct their own due diligence before making any decision to buy a security. This is not an independent research report since the author received funds of twenty five thousand dollars from a third party for preparation and distribution of the material therefore has a conflict of interest.
Contacts
2nd Opinion Research LLC
Clay Mahaffey, 504-525-2161
Permalink: http://www.businesswire.com/news/home/20110311005981/en/2nd-Opinion-Research-Issues-Report-Net-Savings
Thanks mil0x. That was very informative. Never knew there was so much to it. I simply opened an account, did my research and started investing.
Before this conversation gets gay, I'm a female. LOL
Go PSPW!!!